<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Elevated generation of reactive oxygen species (ROS) has been demonstrated during <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> and reperfusion </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="40" ids="18243">Dopamine</z:chebi> (<z:mp ids='MP_0000273'>DA</z:mp>) autooxidation may contribute to increased ROS generation </plain></SENT>
<SENT sid="2" pm="."><plain>The novel neuroprotective agent AM-36 has <z:chebi fb="11" ids="22586">antioxidant</z:chebi> and <z:chebi fb="0" ids="29101">Na(+)</z:chebi> channel blocking activity and reduces neuronal damage in both cortex and striatum after middle cerebral artery (<z:chebi fb="70" ids="34342">MCA</z:chebi>) occlusion </plain></SENT>
<SENT sid="3" pm="."><plain>Here we sought in vivo evidence of the ability of AM-36 to inhibit intrastriatal ROS generation and <z:mp ids='MP_0000273'>DA</z:mp> release after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="1" ids="30762">Salicylate</z:chebi> hydroxylation coupled with in vivo microdialysis in the striatum of conscious Long Evans rats was performed during <z:chebi fb="70" ids="34342">MCA</z:chebi> occlusion by perivascular microinjection of endothelin-1 (ET-1) </plain></SENT>
<SENT sid="5" pm="."><plain>AM-36 (6 mg/kg) was administered intraperitoneally 30 min after <z:chebi fb="70" ids="34342">MCA</z:chebi> occlusion </plain></SENT>
<SENT sid="6" pm="."><plain>Dialysates were analysed using high performance liquid chromatography with electrochemical detection for the <z:chebi fb="1" ids="30762">salicylate</z:chebi> hydroxylation product, <z:chebi fb="0" ids="18026">2,3-dihydroxybenzoic acid</z:chebi> (2,3 DHBA) and for <z:mp ids='MP_0000273'>DA</z:mp> and metabolites </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="70" ids="34342">MCA</z:chebi> occlusion resulted in a marked increase in 2,3 DHBA and a secondary increase in <z:hpo ids='HP_0000001'>all</z:hpo> analytes, 180-300 min later </plain></SENT>
<SENT sid="8" pm="."><plain>Increased <z:mp ids='MP_0000273'>DA</z:mp> release coincided with 2,3 DHBA formation </plain></SENT>
<SENT sid="9" pm="."><plain>AM-36 significantly reduced <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> induced increases in 2,3 DHBA and <z:mp ids='MP_0000273'>DA</z:mp>, and <z:mpath ids='MPATH_124'>infarct</z:mpath> volume in the striatum </plain></SENT>
<SENT sid="10" pm="."><plain>Significant improvements in a battery of behavioural tests was also found in AM-36 treated rats </plain></SENT>
<SENT sid="11" pm="."><plain>This study has demonstrated profound inhibition of ROS generation by a novel compound with <z:chebi fb="11" ids="22586">antioxidant</z:chebi> activity, administered post-<z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> in conscious rats </plain></SENT>
</text></document>